Benralizumab for Chronic Spontaneous Urticaria
Jonathan A. Bernstein, Umesh Singh, Marepalli B. Rao, Karen Berendts, Xiang Zhang, Diya F. Mutasim
Abstract
Benralizumab for Chronic Spontaneous Urticaria Benralizumab, an anti–interleukin-5-receptor antibody, was evaluated in a 24-week study involving 12 patients with chronic spontaneous urticaria. The ...
Topics & Concepts
BenralizumabMedicineChronic urticariaAntibodyDermatologyImmunologyAsthmaMepolizumabEosinophilUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaAutoimmune Bullous Skin Diseases